Venous thromboembolism incidence similar in obese, nonobese patients taking enoxaparin
No statistically significant difference exists in venous thromboembolism incidence between obese, overweight and nonobese hospitalized patients receiving approved enoxaparin prophylaxis doses, reports a recent study.
A total of 428 patients were included, of which eight (1.9 percent) had venous thromboembolism (three in the nonobese group; two in the overweight group; three in the obese group). There were no statistically significant differences found between the three groups (p=0.81).
Differences were also not statistically significant between overweight (odds ratio [OR], 0.685; 95 percent CI, 0.115–4.095), obese (OR, 0.797; 0.353–1.796), and combined overweight and obese (OR, 0.656; 0.154–2.799) groups compared to patients with normal body weight when incidence of venous thromboembolism was adjusted for age and sex.
This retrospective cohort study compared the incidence of venous thromboembolism between obese and nonobese hospitalized patients who received prophylactic enoxaparin doses and described enoxaparin dosing strategies used in obese patients.
Participants included those who were admitted to Parkview Regional Medical Center, Parkview Hospital or Parkview Orthopedic Hospital between September 2011 and August 2012 and received at least one dose of 30-mg enoxaparin twice daily or 40-mg enoxaparin once daily for venous thromboembolism prophylaxis.
Patients were classified into three groups based on their body mass index (BMI): group 1 (nonobese: BMI <25 kg/m2), group 2 (overweight: BMI ≥25 kg/m2 but <30 kg/m2) and group 3 (obese: BMI ≥30 kg/m2). Venous thromboembolism occurrence within 90 days, considering day 1 of hospitalization as day 1, was the primary endpoint.